About
A story born of a physician — and a patient
CuraVac was founded in 2003 by Dr Stéphane Huberty, a Belgian physician living with myasthenia gravis, with a clear purpose: transforming a scientific discovery into a tangible treatment for patients.
About Us
CuraVac is a biotechnology company specializing in the development of Targeted Active Therapies for autoimmune diseases. Founded by Dr Stéphane Huberty, CuraVac has, from its earliest days, benefited from the guidance of Prof. J. Edwin Blalock, the scientist who discovered the complementary peptide technique.
Following approval in November 2015, 24 patients received three injections in a Phase 1b trial at Antwerp University Hospital (UZA). The final results, reported in June 2018, showed an excellent safety and tolerability profile and indicated signs of efficacy. Dr Huberty himself is completely asymptomatic today, after self‑administering the treatment in 2010.
CuraVac’s primary mission is to tackle myasthenia gravis — affecting more than one in 5,000 people — as a first indication, then extend its technology platform to other autoimmune diseases that together affect over 5% of the Western population. The company is now preparing a Phase 2 efficacy trial in humans with an enhanced formulation (CV‑MG02) and is on the verge of finalizing the product development of CV-MG01, which will soon be available to dogs with canine myasthenia gravis.
2003
year founded
24
patients · Phase 1b
€18M
raised to date
EMA · FDA
orphan drug
Our Story
From Discovery to Phase 2
Shortly after its founding, CuraVac acquired the complementary peptide patent, secured initial funding, and structured itself as an agile management company at the centre of a network of expert partnerships and specialized subcontractors.
-
2003
Founding
Creation of CuraVac, acquisition of the complementary peptide patent, fundraising, and organization as a management company at the center of a network of collaborations and subcontractors.
-
2006
MG immunization patent
Filing of the patent for immunization against myasthenia gravis.
-
2007
Demonstrating efficacy, from bench to bedside
Publication of a key article demonstrating that the therapy works in naturally occurring myasthenia gravis in companion dogs. Following this milestone, Nicolas Havelange joins CuraVac and, together with Dr Huberty, drives the transition of the technique from the laboratory to clinical development.
-
2009
Human formulation
Manufacture of a first human formulation of the therapy, in compliance with GLP and GMP guidelines.
-
2009
Orphan drug designation in Europe
Orphan drug designation in Europe, granted by a team of independent experts from the 27 member states.
-
2011
FDA orphan drug designation
The FDA grants orphan drug designation in the United States.
-
2013
The MYASTERIX consortium
The MG therapeutic immunization project is selected by an independent jury as one of seven funded initiatives. CuraVac then establishes a European consortium uniting four companies and a university medical center under the FP7 program “Innovation in Health.”
-
2015
Authorization of the Phase 1b trial
Authorization of the Phase 1b clinical trial (November): 24 patients receive three injections of CV-MG01 at Antwerp University Hospital (UZA).
-
2016
FDA authorization for an American patient
The FDA authorizes the administration of CV-MG to an American patient, who has remained symptom-free to date.
-
2018
Successful Phase 1b
Final results (June): excellent tolerability and safety profile, together with signs of efficacy, calling for a Phase 2 efficacy trial with a more potent formulation, CV-MG02.
-
2022
New patents
New patents for immunization (therapeutic and prophylactic treatment of myasthenia gravis), the carrier protein of the peptide antigen, and the method for producing the periplasmic form of the CRM197 protein.
-
2023
Uto, first dog treated with CV-MG01
Compassionate administration of CV-MG01 to Uto, a Golden Retriever with severe myasthenia gravis: complete remission after three injections, with no relapse to date.
-
2025
"Limited Markets" status (EMA)
The EMA grants CV-MG01 immunological veterinary medicinal product status for limited markets (IVMP), significantly accelerating the path toward veterinary marketing authorization.
-
2026
Teddy, on the road to recovery
Compassionate administration of CV-MG01 to Teddy, a Labradoodle with myasthenia gravis, now on the road to recovery.
-
Today
Heading for Phase 2
CuraVac is preparing two near-term milestones supported by the Public Services of Wallonia: in humans, the Phase 2 efficacy trial with CV-MG02; in dogs, the final product development of CV-MG01 before veterinary marketing authorization. The company is currently seeking investors to reach both.
“They did not know it was impossible, so they did it.”
Meet the team
Behind this story stand eight key people and a leading advisory board, including Prof. J. Edwin Blalock, discoverer of the complementary peptide immunization technology